4.7 Article

Characterisation of clinical and food animal Escherichia coli isolates producing CTX-M-15 extended-spectrum β-lactamase belonging to ST410 phylogroup A

期刊

出版社

ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2011.01.001

关键词

CTX-M-15; Phylogroup A; Meat; ST410

资金

  1. Ministerio de Ciencia e Innovacion (Instituto de Salud Carlos III, Fondo de Investigacion Sanitaria) [REIPI- RD06/0008-1018, PS09/01273, PI070190]
  2. Ministerio de Educacion y Ciencia [AGL-2008-02129, PI-0048/2008, P09-CTS-5259, 09TAL007261PR, 2007/000044-0]
  3. European Regional Development Fund (ERDF)

向作者/读者索取更多资源

Seven phylogroup A CTX-M-15-producing Escherichia coli isolates recovered from clinical and meat samples were further characterised. All of them belonged to sequence type ST410. Only 2 of the 22 virulence genes investigated were detected. All isolates carried the fimH gene encoding type 1 fimbriae, and five isolates harboured the iucD gene encoding aerobactin siderophore. A group of five isolates showed 81.2% similarity by pulsed-field gel electrophoresis (PFGE), comprising three clinical isolates belonging to ONT:H9 and two food isolates belonging to O55:H9. Different HpaI digestion patterns were observed for plasmids, but all of them belonged to IncFIB group and harboured bla(CTX-M-15) associated with bla(OXA-1), bla(TEM), tetA, catB3 and aac(6`)-Ib surrounded by an identical genetic environment. These findings showed the possibility of lateral gene transfer of bla(CTX-M-15) as well as other antibiotic resistance determinants between low-virulence food and clinical isolates. (c) 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Infectious Diseases

Staphylococcus lugdunensis bacteremia: clinical implications of single set positive blood cultures

Toshiharu Sasaki, Yohei Doi

Summary: This study investigated cases of S. lugdunensis bacteremia and found that the clinical significance of single-positive cases is uncertain. Among all cases, only a small subset of low-risk patients did not require antimicrobial therapy, and they had no adverse clinical consequences.

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2023)

Article Immunology

Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19): The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study

Hiroshi Mukae, Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Hiroki Sakaguchi, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Keiko Baba, Yuko Tsuge, Takeki Uehara

Summary: This study evaluated the efficacy and safety of ensitrelvir for mild-to-moderate COVID-19 during the Omicron epidemic. The results showed that ensitrelvir treatment significantly reduced the SARS-CoV-2 titer compared to placebo. However, there was no significant difference in the total score of the 12 COVID-19 symptoms. Overall, ensitrelvir demonstrated favorable antiviral efficacy and potential clinical benefit with an acceptable safety profile.

CLINICAL INFECTIOUS DISEASES (2023)

Article Infectious Diseases

Outcomes of octogenarians and nonactogenarians with Pseudomonas aeruginosa bacteremia: a multicenter retrospective study

Alaa Atamna, Ili Margalit, Gida Ayada, Tanya Babich, Pontus Naucler, John Karlsson Valik, Christian G. Giske, Natividad Benito, Ruben Cardona, Alba Rivera, Celine Pulcini, Manal Abdel Fattah, Justine Haquin, Alasdair Macgowan, Bibiana Chazan, Anna Yanovskay, Ronen Ben Ami, Michal Landes, Lior Nesher, Adi Zaidman-Shimshovitz, Kate McCarthy, David L. Paterson, Evelina Tacconelli, Michael Buhl, Susanna Mauer, Jesus Rodriguez-Bano, Marina de Cueto, Antonio Oliver, Enrique Ruiz de Gopegui, Angela Cano, Isabel Machuca, Monica Gozalo-Marguello, Luis Martinez-Martinez, Eva M. Gonzalez-Barbera, Iris Gomez Alfaro, Miguel Salavert, Bojana Beovic, Andreja Saje, Manica Mueller-Premru, Leonardo Pagani, Virginie Vitrat, Diamantis Kofteridis, Maria Zacharioudaki, Sofia Maraki, Yulia Weissman, Mical Paul, Yaakov Dickstei, Dafna Yahav

Summary: This study aimed to evaluate outcomes of P. aeruginosa bacteremia among older adults (> 80 years) and found that disease severity, place of acquisition, and background conditions were associated with mortality, while antimicrobial regimen was not. Therefore, preventive efforts and early diagnosis might be beneficial for improving outcomes in older adults with P. aeruginosa bacteremia.

INFECTION (2023)

Letter Infectious Diseases

Serum IFN-γ and RNAemia temporal profiles as biomarkers of severe COVID-19 in solid organ transplant and immunocompetent patients

Sonsoles Salto-Alejandre, Marta Carretero-Ledesma, Pedro Camacho-Martinez, Judith Berastegui-Cabrera, Carmen Infante, Regino Rodriguez-Alvarez, Jorge Alba, Patricia Perez-Palacios, Emilio Garcia-Diaz, Cristina Roca, Julia Praena, Maria Jose Blanco-Vidal, Sonia Santibanez, Rocio Valverde-Ortiz, Javier Nieto-Arana, Concepcion Garcia-Garcia, David Gutierrez-Campos, Natalia Maldonado, Gabriel Bernal, Miguel Angel Gomez-Bravo, Jose Manuel Sobrino, Manuela Aguilar-Guisado, Rocio Alvarez-Marin, Josune Goikoetxea-Aguirre, Jose Antonio Oteo, Zaira R. Palacios-Baena, Alvaro Pascual, Jose Antonio Lepe, Jesus Rodriguez-Bano, Jose Miguel Cisneros, Jeronimo Pachon, Javier Sanchez-Cespedes, Elisa Cordero

JOURNAL OF INFECTION (2023)

Article Microbiology

Synergistic Effect of SOS Response and GATC Methylome Suppression on Antibiotic Stress Survival in Escherichia coli

S. Diaz-Diaz, E. Recacha, Marina R. Pulido, Maria Romero-Munoz, B. de Gregorio-Iaria, F. Docobo-Perez, A. Pascual, J. M. Rodriguez-Martinez

Summary: The suppression of the SOS response and Dam methylation system enhances the in vitro activity of quinolones. Dual targeting of the recA (SOS response) and Dam methylation system genes increases the sensitivity of Escherichia coli to quinolones, even in a resistant strain model. This genetic and microbiological approach demonstrates the potential for preventing the evolution of resistance by suppressing both systems in quinolone-resistant strains.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2023)

Article Infectious Diseases

Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial

Jesus Sojo-Dorado, Inmaculada Lopez-Hernandez, Alicia Hernandez-Torres, Pilar Retamar-Gentil, Esperanza Merino de Lucas, Laura Escola-Verge, Elena Bereciartua, Elisa Garcia-Vazquez, Vicente Pintado, Lucia Boix-Palop, Clara Natera-Kindelan, Luisa Sorli, Nuria Borrell, Concha Amador-Prous, Evelyn Shaw, Alfredo Jover-Saenz, Jose Molina, Rosa M. Martinez-Alvarez, Carlos J. Duenas, Jorge Calvo-Montes, Maria Lecuona, Virginia Pomar, Irene Borreguero, Virginia Palomo-Jimenez, Fernando Docobo-Perez, Alvaro Pascual, Jesus Rodriguez-Bano

Summary: This study compared the effectiveness and safety of fosfomycin trometamol and other oral drugs as step-down therapy for multidrug-resistant Escherichia coli (MDR-Ec) induced bacteremic urinary tract infections (BUTI). The results showed no significant difference in clinical and microbiological cure between fosfomycin trometamol and other drugs, but the relapse rate was higher in the fosfomycin trometamol group. Therefore, fosfomycin trometamol may be a reasonable option for step-down therapy in BUTI, but the relapse rate needs further evaluation.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2023)

Article Medicine, General & Internal

Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers

Laure F. Pittet, Nicole L. Messina, Francesca Orsini, Cecilia L. Moore, Veronica Abruzzo, Simone Barry, Rhian Bonnici, Marc Bonten, John Campbell, Julio Croda, Margareth Dalcolmo, Kaya Gardiner, Grace Gell, Susie Germano, Adriano Gomes-Silva, Casey Goodall, Amanda Gwee, Tenaya Jamieson, Bruno Jardim, Tobias R. Kollmann, Marcus V. G. Lacerda, Katherine J. Lee, Michaela Lucas, David J. Lynn, Laurens Manning, Helen S. Marshall, Ellie McDonald, Craig F. Munns, Suellen Nicholson, Abby O'Connell, Roberto D. de Oliveira, Susan Perlen, Kirsten P. Perrett, Cristina Prat-Aymerich, Peter C. Richmond, Jesus Rodriguez-Bano, Glauce dos Santos, Patricia V. da Silva, Jia Wei Teo, Paola Villanueva, Adilia Warris, Nicholas J. Wood, Andrew Davidson, Nigel Curtis

Summary: In this international trial, healthcare workers were randomly assigned to receive either the BCG-Denmark vaccine or a saline placebo. After 6 months, it was found that the BCG vaccine did not reduce the risk of symptomatic or severe Covid-19 compared to placebo.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Article Multidisciplinary Sciences

Efficacy and safety of different antimicrobial DURATions for the treatment of Infections associated with Osteosynthesis Material implanted after long bone fractures (DURATIOM): Protocol for a randomized, pragmatic trial

Carmen Garrigos, Clara Maria Rosso-Fernandez, Irene Borreguero, Patricia Rodriguez, Raquel Garcia-Albea, Jose Maria Bravo-Ferrer, Jesus Rodriguez-Bano, Maria Dolores del Toro

Summary: This study aims to investigate the optimal duration of antibiotic treatment in infection associated with osteosynthesis material (IOM) after long bone fractures. The hypothesis is that a shorter duration of antibiotic treatment can reduce antibiotic exposure, control antimicrobial resistance, and lower adverse events and costs, while still maintaining a high cure rate and functional recovery.

PLOS ONE (2023)

Article Microbiology

A compensatory RNase E variation increases Iron Piracy and Virulence in multidrug-resistant Pseudomonas aeruginosa during Macrophage infection

Mylene Vaillancourt, Anna Clara Milesi Galdino, Sam P. Limsuwannarot, Diana Celedonio, Elizabeth Dimitrova, Matthew Broerman, Catherine Bresee, Yohei Doi, Janet S. Lee, William C. Parks, Peter Jorth

Summary: This study investigates the virulence mechanisms of antibiotic resistant Pseudomonas aeruginosa in cystic fibrosis (CF) patients. It reveals that a mutation in the RNase E gene leads to increased production of siderophores, which damage macrophage cell membranes and cause cell death. The study also suggests that gallium can reduce the virulence of RNase E variants and may serve as a precision therapy for these infections.

PLOS PATHOGENS (2023)

Article Immunology

Phagocytosis is a primary determinant of pulmonary clearance of clinical Klebsiella pneumoniae isolates

Rick van der Geest, Hongye Fan, Hernan F. Penaloza, William G. Bain, Zeyu Xiong, Naina Kohli, Emily Larson, Mara L. G. Sullivan, Jonathan M. Franks, Donna B. Stolz, Ryota Ito, Kong Chen, Yohei Doi, Melanie J. Harriff, Janet S. Lee

Summary: This study found heterogeneity in the sensitivity of clinical Kp isolates to macrophage phagocytic uptake, and demonstrated that phagocytosis is a significant determinant of the pathogenicity of Kp in the lungs.

FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2023)

Article Microbiology

In Vitro Activity of Cefiderocol Compared to Other Antimicrobials against a Collection of Metallo-Beta-Lactamase-Producing Gram-Negative Bacilli from Southern Spain

M. Delgado-Valverde, I. Portillo-Calderon, E. Recacha, P. Perez-Palacios, A. Pascual

Summary: This study compared the in vitro activity of cefiderocol with other antimicrobials against MBL-GNB isolates from hospitals in Andalusia, Spain. Cefiderocol showed potent activity against all isolates tested, regardless of breakpoint values.

MICROBIOLOGY SPECTRUM (2023)

Article Microbiology

Daily fosfomycin versus levofloxacin for complicated urinary tract infections

Nadine Rouphael, Patricia Winokur, Michael C. Keefer, Jessica Traenkner, Ana Drobeniuc, Yohei Doi, Sonal Munsiff, Vance G. Fowler, Scott Evans, Randolph E. Oler, Bonifride Tuyishimire, Marina Lee, Varduhi Ghazaryan, Henry F. Chambers

Summary: Concerns over resistance and safety have been identified in the current treatment regimen for complicated urinary tract infections. Fosfomycin is a drug that is routinely used for the treatment of uncomplicated cystitis. This study shows that fosfomycin could be an oral alternative as step-down therapy for the treatment of complicated urinary tract infections, with a clinical cure rate comparable to levofloxacin but a lower microbiological success rate 3 weeks from start of antibiotics.
Article Microbiology

Genomic epidemiology and antibiotic susceptibility profiling of uropathogenic Escherichia coli among children in the United States

Rauf Salamzade, Christi L. McElheny, Abigail L. Manson, Ashlee M. Earl, Nader Shaikh, Yohei Doi

Summary: Escherichia coli is the most common cause of urinary tract infections (UTIs) in children. However, the mechanisms of virulence and antibiotic resistance, as well as the population structure of this species, are poorly understood in this age group. This study examined the genetic markers and population structure of uropathogenic E. coli (UPEC) in children with UTIs. The results revealed similarities between UPEC populations in children and adults, with certain genetic markers being more common in pediatric pyelonephritis cases. Additionally, antibiotic resistance was correlated with known genetic markers, and a fimbrial gene allele was found to confer a selective advantage for UPEC.

MSPHERE (2023)

Article Microbiology

Comparison of three rapid diagnostic tests for bloodstream infections using Benefit-risk Evaluation Framework (BED-FRAME)

Richard D. Smith, Min Zhan, Shanshan Zhang, Surbhi Leekha, Anthony Harris, Yohei Doi, Scott Evans, J. Kristie Johnson, Robert K. Ernst

Summary: This study evaluated a new rapid lipid analysis technique called FLAT MS for direct identification of pathogens from blood cultures. FLAT MS showed slight differences in accuracy compared to other FDA-approved methods for identifying Gram-positive bacteria, Gram-negative bacteria, and yeast. The time-to-results and hands-on time of FLAT MS were comparable to other methods.

JOURNAL OF CLINICAL MICROBIOLOGY (2023)

Review Infectious Diseases

Lenacapavir: A novel injectable HIV-1 capsid inhibitor

Allison M. Hitchcock, Wesley D. Kufel, Keri A. Mastro Dwyer, Eric F. Sidman

Summary: Lenacapavir is a novel HIV-1 treatment option for patients with multidrug-resistant (MDR) HIV-1 infection. It has a favorable pharmacokinetic profile and has shown good tolerability and efficacy in clinical trials.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)

Article Infectious Diseases

Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

Roberta Gagliardini, Alessandro Tavelli, Stefano Rusconi, Sergio Lo Caputo, Vincenzo Spagnuolo, Maria Mercedes Santoro, Andrea Costantini, Alessandra Vergori, Franco Maggiolo, Andrea Giacomelli, Giulia Burastero, Giordano Madeddu, Eugenia Quiros Roldan, Antonella d'Arminio Monforte, Andrea Antinori, Alessandro Cozzi-Lepri

Summary: This study evaluated multiple treatment failures to modern antiretroviral therapy in HIV-infected individuals and found that approximately 4% of them were difficult to treat. The difficult to treat group, compared to the non-difficult to treat group, was characterized by older age, higher prevalence of AIDS, lower CD4+ cell count, and higher risk of treatment failure.

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2024)